中国儿童银屑病诊疗专家共识（2021）

doi:10.35541/cjd.20201065

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (7): 559-581.doi: 10.35541/cjd.20201065

中国儿童银屑病诊疗专家共识（2021）

中华医学会皮肤性病学分会银屑病学组中华医学会皮肤性病学分会儿童学组

中华医学会皮肤性病学分会银屑病学组中华医学会皮肤性病学分会儿童学组

收稿日期:2020-11-03 修回日期:2021-04-10 发布日期:2021-07-02
通讯作者: 张锡宝；马琳；张学军 E-mail:zxibao@126.com; bch_maleen@aliyun.com; ayzxj@vip.sina.com

Consensus on the diagnosis and treatment of childhood psoriasis in China （2021）

Committee on Psoriasis, Chinese Society of Dermatology; Committee on Children, Chinese Society of Dermatology

Committee on Psoriasis, Chinese Society of Dermatology; Committee on Children, Chinese Society of Dermatology

Received:2020-11-03 Revised:2021-04-10 Published:2021-07-02
Contact: Zhang Xibao; Ma Lin; Zhang Xuejun E-mail:zxibao@126.com; bch_maleen@aliyun.com; ayzxj@vip.sina.com

摘要/Abstract

摘要： 【摘要】儿童银屑病是一种发生于儿童（年龄 < 18岁）、由遗传和环境因素（如感染等）共同作用诱发的慢性、复发性、免疫性、系统性皮肤病。儿童银屑病临床表现复杂，型别差异大。因儿童的特殊生理特点，在治疗方面更应注重安全性。相对于成人，儿童银屑病的治疗方法较局限且具有挑战性，如系统药物的理想治疗剂量、长期治疗产生的不良反应、联合用药的选择、药物的转换等尚未明确。许多药物，包括局部药物和系统药物未被批准用于治疗儿童银屑病。建立儿童银屑病诊疗共识的目的是更加有效、科学地规范儿童银屑病诊疗管理，指导医师及时、有效地控制儿童银屑病发生与发展，改善和提高患儿及家庭生活质量，帮助患儿尽可能健康地发育和成长。

关键词: 银屑病, 儿童, 诊断, 治疗, 诊疗准则

Abstract: 【Abstract】 Childhood psoriasis is an immune-mediated chronic, recurrent, systemic skin disease induced by both genetic and environmental factors （e.g., infection, etc.） and occurring in children aged under 18 years. Its clinical manifestations are complex and vary widely between different types. Because of the special physiological condition of children, more attention should be paid to safety of treatment. Compared with adults, the treatment of psoriasis in children is more challenging due to limited options. For example, the ideal therapeutic dose of systemic drugs, adverse effects of long-term treatment, the choice of drug combination, and the conversion of drugs have not been clarified. Many drugs, including topical and systemic drugs, have not been approved for the treatment of childhood psoriasis. The purpose of this consensus is to standardize the diagnosis and treatment of childhood psoriasis more effectively and scientifically, to guide physicians to timely and effective control of occurrence and development of childhood psoriasis, to improve the quality of life of children and their families, and to help children develop and grow as healthily as possible.

Key words: Psoriasis, Child, Diagnosis, Therapy, Practice guideline

中华医学会皮肤性病学分会银屑病学组中华医学会皮肤性病学分会儿童学组. 中国儿童银屑病诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021,54(7):559-581. doi:10.35541/cjd.20201065

Committee on Psoriasis, Chinese Society of Dermatology, Committee on Children, Chinese Society of Dermatology. Consensus on the diagnosis and treatment of childhood psoriasis in China （2021）[J]. Chinese Journal of Dermatology, 2021, 54(7): 559-581.doi:10.35541/cjd.20201065

参考文献 231

［1］	Menter A, Cordoro KM, Davis D, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients［J］. J Am Acad Dermatol, 2020,82（1）:161⁃201. doi: 10.1016/j.jaad.2019.08.049.
［2］	Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children［J］. Br J Dermatol, 2010,162（3）:633⁃636. doi: 10.1111/j.1365⁃2133.2009.09593.x.
［3］	Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema［J］. Dermatology, 2015,231（1）:35⁃40. doi: 10.1159/000381913.
［4］	Osier E, Wang AS, Tollefson MM, et al. Pediatric psoriasis comorbidity screening guidelines［J］. JAMA Dermatol, 2017,153（7）:698⁃704. doi: 10.1001/jamadermatol.2017.0499.
［5］	Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: a clinical review of 1 262 cases［J］. Pediatr Dermatol, 2001,18（3）:188⁃198. doi: 10.1046/j.1525⁃1470.2001.018003188.x.
［6］	Stoll ML, Mellins ED. Psoriatic arthritis in childhood: a commentary on the controversy［J］. Clin Immunol, 2020,214:108396. doi: 10.1016/j.clim.2020.108396.
［7］	Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents⁃short version part 1［J］. J Dtsch Dermatol Ges, 2019,17（8）:856⁃870. doi: 10.1111/ddg.13907.
［8］	Eichenfield LF, Paller AS, Tom WL, et al. Pediatric psoriasis: evolving perspectives［J］. Pediatr Dermatol, 2018,35（2）:170⁃181. doi: 10.1111/pde.13382.
［9］	Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities［J］. Paediatr Drugs, 2015,17（5）:373⁃384. doi: 10.1007/s40272⁃015⁃0137⁃1.
［10］	Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence［J］. J Invest Dermatol, 2013,133（2）:377⁃385. doi: 10.1038/jid.2012.339.
［11］	Beylot C, Puissant A, Bioulac P, et al. Particular clinical features of psoriasis in infants and chidren［J］. Acta Derm Venereol Suppl （Stockh）, 1979,87:95⁃97.
［12］	Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients［J］. Dermatologica, 1974,148（1）:1⁃18. doi: 10.1159/000251595.
［13］	Farber EM, Nall L. Childhood psoriasis［J］. Cutis, 1999,64（5）:309⁃314.
［14］	Tollefson MM. Diagnosis and management of psoriasis in children［J］. Pediatr Clin North Am, 2014,61（2）:261⁃277. doi: 10.1016/j.pcl.2013.11.003.
［15］	Relvas M, Torres T. Pediatric psoriasis［J］. Am J Clin Dermatol, 2017,18（6）:797⁃811. doi: 10.1007/s40257⁃017⁃0294⁃9.
［16］	Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（2）:205⁃212. doi: 10.1111/jdv.13854.
［17］	Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011［J］. Dermatology, 2012,225（2）:121⁃126. doi: 10.1159/000342180.
［18］	Linder MD, Piaserico S, Augustin M, et al. Psoriasis ⁃ the life course approach［J］. Acta Derm Venereol, 2016,96（217）:102⁃108. doi: 10.2340/00015555⁃2430.
［19］	Roberson ED, Bowcock AM. Psoriasis genetics: breaking the barrier［J］. Trends Genet, 2010,26（9）:415⁃423. doi: 10.1016/j.tig.2010.06.006.
［20］	Boehncke WH, Schön MP. Psoriasis［J］. Lancet, 2015,386（9997）:983⁃994. doi: 10.1016/S0140⁃6736（14）61909⁃7.
［21］	Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA⁃Cw*0602 positive and negative psoriasis patients⁃⁃an analysis of 1019 HLA⁃C⁃ and HLA⁃B⁃typed patients［J］. J Invest Dermatol, 2006,126（4）:740⁃745. doi: 10.1038/sj.jid.5700118.
［22］	Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain⁃of⁃function variants［J］. J Dermatol Sci, 2014,74（3）:187⁃192. doi: 10. 1016/j.jdermsci.2014.02.006.
［23］	Silverberg NB. Update on pediatric psoriasis, part 1: clinical features and demographics［J］. Cutis, 2010,86（3）:118⁃124.
［24］	Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study［J］. Br J Dermatol, 2003,149（3）:530⁃534. doi: 10.1046/j.1365⁃2133.2003.05552.x.
［25］	Gupta MA, Gupta AK, Watteel GN. Cigarette smoking in men may be a risk factor for increased severity of psoriasis of the extremities［J］. Br J Dermatol, 1996,135（5）:859⁃860. doi: 10. 1111/j.1365⁃2133.1996.tb03909.x.
［26］	Ozden MG, Tekin NS, Gürer MA, et al. Environmental risk factors in pediatric psoriasis: a multicenter case⁃control study［J］. Pediatr Dermatol, 2011,28（3）:306⁃312. doi: 10.1111/j. 1525⁃1470.2011.01408.x.
［27］	Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children［J］. J Pediatr, 2011,159（4）:577⁃583. doi: 10.1016/j.jpeds.2011.03.006.
［28］	Balato A, Scalvenzi M, Cirillo T, et al. Psoriasis in children: a review［J］. Curr Pediatr Rev, 2015,11（1）:10⁃26. doi: 10.2174/1573400511666150504125456.
［29］	丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查［J］. 中国皮肤性病学杂志, 2010,24（7）:598⁃601.
［30］	Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: a population⁃based study［J］. J Am Acad Dermatol, 2010,62（6）:979⁃987. doi: 10.1016/j.jaad.2009.07. 029.
［31］	Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population⁃based study［J］. Arch Dermatol, 2005,141（12）:1537⁃1541. doi: 10.1001/archderm.141.12.1537.
［32］	Kwon HH, Na SJ, Jo SJ, et al. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic［J］. J Dermatol, 2012,39（3）:260⁃264. doi: 10.1111/j.1346⁃8138.2011.01452.x.
［33］	Chiam LY, de Jager ME, Giam YC, et al. Juvenile psoriasis in European and Asian children: similarities and differences［J］. Br J Dermatol, 2011,164（5）:1101⁃1103. doi: 10.1111/j.1365⁃2133.2010.10196.x.
［34］	Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis［J］. Lancet, 2007,370（9583）:263⁃271. doi: 10.1016/S0140⁃6736（07）61128⁃3.
［35］	Benoit S, Hamm H. Childhood psoriasis［J］. Clin Dermatol, 2007,25（6）:555⁃562. doi: 10.1016/j.clindermatol.2007.08.009.
［36］	Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States［J］. Pediatr Dermatol, 2013,30（4）:424⁃428. doi: 10.1111/pde.12072.
［37］	Al⁃Mutairi N, Manchanda Y, Nour⁃Eldin O. Nail changes in childhood psoriasis: a study from Kuwait［J］. Pediatr Dermatol, 2007,24（1）:7⁃10. doi: 10.1111/j.1525⁃1470.2007.00324.x.
［38］	Fortina AB, Bardazzi F, Berti S, et al. Treatment of severe psoriasis in children: recommendations of an Italian expert group［J］. Eur J Pediatr, 2017,176（10）:1339⁃1354. doi: 10. 1007/s00431⁃017⁃2985⁃x.
［39］	Li M, Han J, Lu Z, et al. Prevalent and rare mutations in IL⁃36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris［J］. J Invest Dermatol, 2013,133（11）:2637⁃2639. doi: 10.1038/jid.2013.267.
［40］	Qin P, Zhang Q, Chen M, et al. Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis［J］. J Invest Dermatol, 2014,134（12）:2994⁃2996. doi: 10.1038/jid.2014.269.
［41］	Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP［J］. J Dermatol, 2018,45（11）:1235⁃1270. doi: 10.1111/1346⁃8138.14523.
［42］	Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1792⁃1799. doi: 10.1111/jdv. 14386.
［43］	Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups［J］. Curr Opin Rheumatol, 2011,23（5）:437⁃443. doi: 10.1097/BOR.0b013e328348b278.
［44］	Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations［J］. Arthritis Rheum, 2006,54（11）:3564⁃3572. doi: 10.1002/art.22173.
［45］	Egeberg A, Khalid U, Gislason GH, et al. Risk of psoriasis in patients with childhood asthma: a Danish nationwide cohort study［J］. Br J Dermatol, 2015,173（1）:159⁃164. doi: 10.1111/bjd.13781.
［46］	Boccardi D, Menni S, La Vecchia C, et al. Overweight and childhood psoriasis［J］. Br J Dermatol, 2009,161（2）:484⁃486. doi: 10.1111/j.1365⁃2133.2009.09276.x.
［47］	Zhu KJ, He SM, Zhang C, et al. Relationship of the body mass index and childhood psoriasis in a Chinese Han population: a hospital⁃based study［J］. J Dermatol, 2012,39（2）:181⁃183. doi: 10.1111/j.1346⁃8138.2011.01281.x.
［48］	Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross⁃sectional study［J］. JAMA Dermatol, 2013,149（2）:166⁃176. doi: 10.1001/jamadermatol.2013.1078.
［49］	Kimball AB, Wu EQ, Guérin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis［J］. J Am Acad Dermatol, 2012,67（4）:651⁃657.e1⁃2. doi: 10.1016/j.jaad.2011.11.948.
［50］	de Jager ME, van de Kerkhof PC, de Jong EM, et al. A cross⁃sectional study using the Children′s Dermatology Life Quality Index （CDLQI） in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores［J］. Br J Dermatol, 2010,163（5）:1099⁃1101. doi: 10. 1111/j.1365⁃2133.2010.09993.x.
［51］	Becker L, Tom WL, Eshagh K, et al. Excess adiposity preceding pediatric psoriasis［J］. JAMA Dermatol, 2014,150（5）:573⁃574. doi: 10.1001/jamadermatol.2014.324.
［52］	Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study［J］. JAMA Dermatol, 2013,149（7）:795⁃801. doi: 10.1001/jamadermatol.2013.722.
［53］	DeBoer MD. Assessing and managing the metabolic syndrome in children and adolescents［J］. Nutrients，2019，11（8）:1788. doi: 10.3390/nu11081788.
［54］	Goldminz AM, Buzney CD, Kim N, et al. Prevalence of the metabolic syndrome in children with psoriatic disease［J］. Pediatr Dermatol, 2013,30（6）:700⁃705. doi: 10.1111/pde.12218.
［55］	Kwa L, Kwa MC, Silverberg JI. Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States［J］. J Am Acad Dermatol, 2017,77（6）:1023⁃1029. doi: 10.1016/j.jaad.2017.08.034.
［56］	Akay A, Pekcanlar A, Bozdag KE, et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus［J］. J Eur Acad Dermatol Venereol, 2002,16（4）:347⁃352. doi: 10.1046/j.1468⁃3083.2002.00467.x.
［57］	Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review［J］. Australas J Dermatol, 2004,45（3）:155⁃159; quiz 160⁃161. doi: 10.1111/j.1440⁃0960.2004.00078.x.
［58］	Lewis⁃Jones MS, Finlay AY. The Children′s Dermatology Life Quality Index （CDLQI）: initial validation and practical use［J］. Br J Dermatol, 1995,132（6）:942⁃949. doi: 10.1111/j.1365⁃2133.1995.tb16953.x.
［59］	Oostveen AM, de Jager ME, van de Kerkhof PC, et al. The influence of treatments in daily clinical practice on the Children′s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child⁃CAPTURE patient registry［J］. Br J Dermatol, 2012,167（1）:145⁃149. doi: 10.1111/j.1365⁃2133.2012.10996.x.
［60］	Lallas A, Kyrgidis A, Tzellos TG, et al. Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea［J］. Br J Dermatol, 2012,166（6）:1198⁃1205. doi: 10.1111/j.1365⁃2133.2012.10868.x.
［61］	Golińska J, Sar⁃Pomian M, Rudnicka L. Dermoscopic features of psoriasis of the skin, scalp and nails ⁃ a systematic review［J］. J Eur Acad Dermatol Venereol, 2019,33（4）:648⁃660. doi: 10.1111/jdv.15344.
［62］	Vázquez⁃López F, Manjón⁃Haces JA, Maldonado⁃Seral C, et al. Dermoscopic features of plaque psoriasis and lichen planus: new observations［J］. Dermatology, 2003,207（2）:151⁃156. doi: 10.1159/000071785.
［63］	Jha AK, Lallas A, Sonthalia S, et al. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy［J］. Dermatol Pract Concept, 2018,8（4）:299⁃302. doi: 10.5826/dpc. 0804a10.
［64］	刘晓洁, 张峻岭, 孔祥君, 等. 寻常性银屑病、慢性湿疹和玫瑰糠疹187例皮肤镜特征分析［J］. 临床皮肤科杂志, 2015,44（8）:484⁃486.
［65］	徐晨琛, 刘洁, 陈典, 等. 皮肤镜在寻常型银屑病与慢性湿疹鉴别诊断中的意义［J］.中华医学杂志, 2014,47（36）:2833⁃2837. doi: 10.3760/cma.j.issn.0376⁃2491.2014.36.008.
［66］	刘华绪, 林燕, 单晓峰, 等. 反射式共聚焦激光扫描显微镜在银屑病诊疗中的应用［J］. 中国麻风皮肤病杂志, 2011,27（7）:488⁃491.
［67］	钟连生, 金鑫, 权晟, 等. 皮肤三维CT在寻常性银屑病诊断中的应用［J］. 中国皮肤性病学杂志, 2011,25（8）:607⁃608.
［68］	Batani A, Brănișteanu DE, Ilie MA, et al. Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy［J］. Exp Ther Med, 2018,15（2）:1241⁃1246. doi: 10.3892/etm.2017.5542.
［69］	Arzberger E, Oliveira A, Massone C, et al. Reflectance confocal microscopy as a noninvasive complementary tool in the diagnosis of psoriatic balanitis［J］. Br J Dermatol, 2017,176（5）:1360⁃1362. doi: 10.1111/bjd.14960.
［70］	Ardigo M, Cota C, Berardesca E, et al. Concordance between in vivo reflectance confocal microscopy and histology in the evaluation of plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2009,23（6）:660⁃667. doi: 10.1111/j.1468⁃3083.2009.03134.x.
［71］	Cucoş M, Crişan M, Lenghel M, et al. Conventional ultrasonography and sonoelastography in the assessment of plaque psoriasis under topical corticosteroid treatment ⁃ work in progress［J］. Med Ultrason, 2014,16（2）:107⁃113. doi: 10.11152/mu.2013.2066.162.mc1mc2.
［72］	Dattola A, Altobelli S, Marsico S, et al. Hypodermal adipose tissue sonoelastography for monitoring treatment response in patients with plaque psoriasis［J］. Photomed Laser Surg, 2017,35（9）:484⁃491. doi: 10.1089/pho.2016.4261.
［73］	Șomlea MC, Boca AN, Pop AD, et al. High⁃frequency ultrasonography of psoriatic skin: a non⁃invasive technique in the evaluation of the entire skin of patients with psoriasis: a pilot study［J］. Exp Ther Med, 2019,18（6）:4981⁃4986. doi: 10. 3892/etm.2019.8140.
［74］	Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis［J］. Pediatr Dermatol, 2000,17（3）:174⁃178. doi: 10.1046/j.1525⁃1470.2000.01746.x.
［75］	Nast A, Kopp IB, Augustin M, et al. Evidence⁃based （S3） guidelines for the treatment of psoriasis vulgaris［J］. J Dtsch Dermatol Ges, 2007,5 Suppl 3:1⁃119. doi: 10.1111/j.1610⁃0387.2007.06172.x.
［76］	Nast A, Kopp I, Augustin M, et al. German evidence⁃based guidelines for the treatment of Psoriasis vulgaris （short version）［J］. Arch Dermatol Res, 2007,299（3）:111⁃138. doi: 10.1007/s00403⁃007⁃0744⁃y.
［77］	Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis［J］. J Am Acad Dermatol, 1991, 25（6 Pt 2）:1166⁃1169. doi: 10.1016/0190⁃9622（91）70319⁃w.
［78］	Katz HI, Hien NT, Prawer SE, et al. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis［J］. Arch Dermatol, 1987,123（10）:1308⁃1311. doi: 10.1001/archderm.123.10.1308.
［79］	Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double⁃blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen［J］. Dermatologica, 1991,183（4）:269⁃274. doi: 10.1159/000247698.
［80］	Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis［J］. J Am Acad Dermatol, 1996,35（2 Pt 1）:268⁃269. doi: 10.1016/s0190⁃9622（96）90349⁃7.
［81］	Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52⁃week, randomised, double⁃blind, safety study of a calcipotriol/betamethasone dipropionate two⁃compound product （Daivobet/Dovobet/Taclonex） in the treatment of psoriasis vulgaris［J］. Dermatology, 2006,213（4）:319⁃326. doi: 10.1159/000096069.
［82］	Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis［J］. J Am Acad Dermatol, 1998,39（4 Pt 1）:590⁃596. doi: 10.1016/s0190⁃9622（98）70008⁃8.
［83］	Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis［J］. J Am Acad Dermatol, 2000,42（6）:1008⁃1011.
［84］	Kaidbey K, Kopper SC, Sefton J, et al. A pilot study to determine the effect of tazarotene gel 0.1% on steroid⁃induced epidermal atrophy［J］. Int J Dermatol, 2001,40（7）:468⁃471. doi: 10.1046/j.1365⁃4362.2001.01234.x.
［85］	Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group［J］. J Am Acad Dermatol, 1995,32（1）:67⁃72. doi: 10. 1016/0190⁃9622（95）90186⁃8.
［86］	Dubertret L, Wallach D, Souteyrand P, et al. Efficacy and safety of calcipotriol （MC 903） ointment in psoriasis vulgaris. A randomized, double⁃blind, right/left comparative, vehicle⁃controlled study［J］. J Am Acad Dermatol, 1992,27（6 Pt 1）:983⁃988. doi: 10.1016/0190⁃9622（92）70299⁃u.
［87］	Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol （MC903） solution and placebo （vehicle of MC903） in the treatment of psoriasis of the scalp［J］. Br J Dermatol, 1994,130（4）:483⁃487. doi: 10.1111/j.1365⁃2133. 1994.tb03382.x.
［88］	Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation （Daivobet） is an effective once⁃daily treatment for psoriasis vulgaris［J］. Dermatology, 2002,205（4）:389⁃393. doi: 10.1159/000066440.
［89］	Kragballe K, Austad J, Barnes L, et al. A 52⁃week randomized safety study of a calcipotriol/betamethasone dipropionate two⁃compound product （Dovobet/Daivobet/Taclonex） in the treatment of psoriasis vulgaris［J］. Br J Dermatol, 2006,154（6）:1155⁃1160. doi: 10.1111/j.1365⁃2133.2006.07236.x.
［90］	Hecker D, Lebwohl M. Topical calcipotriene in combination with UVB phototherapy for psoriasis［J］. Int J Dermatol, 1997,36（4）:302⁃303. doi: 10.1046/j.1365⁃4362.1997.00203.x.
［91］	Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment （Dovonex） in treating children with psoriasis vulgaris［J］. Br J Dermatol, 1996,135（3）:390⁃393.
［92］	Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis［J］. J Am Acad Dermatol, 2004,51（5）:723⁃730. doi: 10.1016/j.jaad. 2004.07.011.
［93］	Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double⁃blind, randomized study［J］. J Am Acad Dermatol, 2004,51（5）:731⁃738. doi: 10.1016/j.jaad.2004.06.010.
［94］	Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force［J］. J Am Acad Dermatol, 2006,54（5）:818⁃823. doi: 10. 1016/j.jaad.2006.01.054.
［95］	Ring J, Barker J, Behrendt H, et al. Review of the potential photo⁃cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum［J］. J Eur Acad Dermatol Venereol, 2005,19（6）:663⁃671. doi: 10. 1111/j.1468⁃3083.2005.01315.x.
［96］	Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults［J］. Dermatology, 2007,214（4）:289⁃295. doi: 10.1159/000100879.
［97］	冯小燕, 李钦峰. 儿童银屑病治疗的进展［J］. 中国中西医结合皮肤性病学杂志, 2017,16（3）:283⁃285.
［98］	刘力豪, 陈敏. 儿童银屑病的治疗［J］. 中国皮肤性病学杂志, 2020,34（6）:711⁃714.
［99］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019,52（10）:667⁃710. doi: 10.35541/cjd.20190847.
［100］	Robbins K, Bissonnette R, Maeda⁃Chubachi T, et al. Phase 2, randomized dose⁃finding study of tapinarof （GSK2894512 cream） for the treatment of plaque psoriasis［J］. J Am Acad Dermatol, 2019,80（3）:714⁃721. doi: 10.1016/j.jaad.2018.10. 037.
［101］	Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis［J］. J Am Acad Dermatol, 2012,67（4）:658⁃664. doi: 10.1016/j.jaad.2011.12.018.
［102］	Guerrier CJ, Porter DI. An open assessment of 0.1% dithranol in a 17% urea base （′Psoradrate′ 0.1%） in the treatment of psoriasis of children［J］. Curr Med Res Opin, 1983,8（6）:446⁃450. doi: 10.1185/03007998309111752.
［103］	Kortuem KR, Davis MD, Witman PM, et al. Results of Goeckerman treatment for psoriasis in children: a 21⁃year retrospective review［J］. Pediatr Dermatol, 2010,27（5）:518⁃524. doi: 10.1111/j.1525⁃1470.2010.01124.x.
［104］	Roelofzen JH, Aben KK, Oldenhof UT, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema［J］. J Invest Dermatol, 2010,130（4）:953⁃961. doi: 10.1038/jid.2009.389.
［105］	Marqueling AL, Cordoro KM. Systemic treatments for severe pediatric psoriasis: a practical approach［J］. Dermatol Clin, 2013,31（2）:267⁃288. doi: 10.1016/j.det.2012.12.005.
［106］	Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents ⁃ Short version part 2［J］. J Dtsch Dermatol Ges, 2019,17（9）:959⁃973. doi: 10.1111/ddg.13936.
［107］	中国康复医学会皮肤病康复专业委员会, 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 紫外线治疗皮肤病临床应用专家共识［J］. 中华皮肤科杂志, 2019,52（12）:872⁃877. doi: 10.35541/cjd.20190617.
［108］	王召阳, 马琳. 儿童银屑病［J］. 皮肤性病诊疗学杂志, 2015,22（5）:399⁃402. doi: 10.3969/j.issn.1674⁃8468.2015.05.018.
［109］	Honigsmann H, Schwarz T, Bolognia LL. Dermatology［M］. 2nd ed. Singapore: Elsevier, 2007:2249⁃2250.
［110］	Pahlajani N, Katz BJ, Lozano AM, et al. Comparison of the efficacy and safety of the 308 nm excimer laser for the treatment of localized psoriasis in adults and in children: a pilot study［J］. Pediatr Dermatol, 2005,22（2）:161⁃165. doi: 10. 1111/j.1525⁃1470.2005.22216.x.
［111］	Hadi SM, Al⁃Quran H, de Sá Earp AP, et al. The use of the 308⁃nm excimer laser for the treatment of psoriasis［J］. Photomed Laser Surg, 2010,28（5）:693⁃695. doi: 10.1089/pho. 2009.2722.
［112］	British Photodermatology Group. British Photodermatology Group guidelines for PUVA［J］. Br J Dermatol, 1994,130（2）:246⁃255. doi: 10.1111/j.1365⁃2133. 1994.tb02910.x.
［113］	Eustace K, Dolman S, Alsharqi A, et al. Use of phototherapy in children［J］. Pediatr Dermatol, 2017,34（2）:150⁃155. doi: 10. 1111/pde.13072.
［114］	Ersoy⁃Evans S, Altaykan A, Sahin S, et al. Phototherapy in childhood［J］. Pediatr Dermatol, 2008,25（6）:599⁃605. doi: 10. 1111/j.1525⁃1470.2008.00773.x.
［115］	Pasić A, Ceović R, Lipozencić J, et al. Phototherapy in pediatric patients［J］. Pediatr Dermatol, 2003,20（1）:71⁃77. doi: 10.1046/j.1525⁃1470.2003.03016.x.
［116］	Holme SA, Anstey AV. Phototherapy and PUVA photochemotherapy in children［J］. Photodermatol Photoimmunol Photomed, 2004,20（2）:69⁃75. doi: 10.1111/j.1600⁃0781.2004. 00084.x.
［117］	Roenigk HH Jr, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines［J］. J Am Acad Dermatol, 1988,19（1 Pt 1）:145⁃156. doi: 10.1016/s0190⁃9622（88）80237⁃8.
［118］	Bronckers I, Seyger M, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis［J］. JAMA Dermatol, 2017,153（11）:1147⁃1157. doi: 10.1001/jamadermatol. 2017.3029.
［119］	Di Lernia V, Bonamonte D, Lasagni C, et al. Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis［J］. Pediatr Dermatol, 2016,33（5）:530⁃535. doi: 10.1111/pde.12940.
［120］	Chen P, Li C, Xue R, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review［J］. J Dermatolog Treat, 2018,29（4）:353⁃363. doi: 10.1080/09546634.2017.1395798.
［121］	Wang Y, Cheng R, Lu Z, et al. Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes［J］. J Dermatol Sci, 2017,85（3）:235⁃240. doi: 10.1016/j.jdermsci.2016.11.008.
［122］	Posso⁃De Los Rios CJ, Pope E, Lara⁃Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics［J］. Pediatr Dermatol, 2014,31（4）:430⁃439. doi: 10. 1111/pde.12351.
［123］	Halverstam CP, Zeichner J, Lebwohl M. Lack of significant skeletal changes after long⁃term, low⁃dose retinoid therapy: case report and review of the literature［J］. J Cutan Med Surg, 2006,10（6）:291⁃299. doi: 10.2310/7750.2006.00065.
［124］	Lee CS, Li K. A review of acitretin for the treatment of psoriasis［J］. Expert Opin Drug Saf, 2009,8（6）:769⁃779. doi: 10.1517/14740330903393732.
［125］	Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics［J］. J Am Acad Dermatol, 2020,82（1）:213⁃221. doi: 10.1016/j.jaad.2019.05.056.
［126］	Martini A, Ravelli A, Avcin T, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization international consensus［J］. J Rheumatol, 2019,46（2）:190⁃197. doi: 10.3899/ jrheum.180168.
［127］	吴凤岐, 杨锡强, 胡坚, 等. 2018年《国际儿童风湿病试验组织（PRINTO）幼年特发性关节炎新分类标准专家共识（启动步骤）》中国专家解读［J］. 中国实用儿科杂志, 2018,33（12）:944⁃949. doi: 10.19538/j.ek2018120604.
［128］	Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study［J］. Clin Exp Rheumatol, 2006,24（5）:599⁃605.
［129］	Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis［J］. Ann Rheum Dis, 2005,64（6）:859⁃864. doi: 10.1136/ard.2004.024463.
［130］	Kalinina Ayuso V, Makhotkina N, van Tent⁃Hoeve M, et al. Pathogenesis of juvenile idiopathic arthritis associated uveitis: the known and unknown［J］. Surv Ophthalmol, 2014,59（5）:517⁃531. doi: 10.1016/j.survophthal.2014.03.002.
［131］	Saeed MU, Raza SH, Goyal S, et al. Etanercept in methotrexate⁃resistant JIA⁃related uveitis［J］. Semin Ophthalmol, 2014,29（1）:1⁃3. doi: 10.3109/08820538.2013.839802.
［132］	Phan C, Beauchet A, Burztejn AC, et al. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（10）:1984⁃1992. doi: 10.1111/jdv.15579.
［133］	Paller AS, Siegfried EC, Pariser DM, et al. Long⁃term safety and efficacy of etanercept in children and adolescents with plaque psoriasis［J］. J Am Acad Dermatol, 2016,74（2）:280⁃287.e1⁃3. doi: 10.1016/j.jaad.2015.09.056.
［134］	Windschall D, Müller T, Becker I, et al. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis⁃related arthritis and psoriasis arthritis［J］. Clin Rheumatol, 2015,34（1）:61⁃69. doi: 10.1007/s10067⁃014⁃2744⁃6.
［135］	Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3.
［136］	Di Lernia V, Bianchi L, Guerriero C, et al. Adalimumab in severe plaque psoriasis of childhood: a multi⁃center, retrospective real⁃life study up to 52 weeks observation［J］. Dermatol Ther, 2019,32（6）:e13091. doi: 10.1111/dth.13091.
［137］	Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate⁃to⁃severe plaque psoriasis: results of the randomized phase 3 CADMUS study［J］. J Am Acad Dermatol, 2015,73（4）:594⁃603. doi: 10.1016/j.jaad.2015.07.002.
［138］	Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients （≥ 6 to < 12 years of age）: efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018.
［139］	Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a Phase 3 double⁃blind randomized, controlled trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:938⁃947. doi: 10.1111/jdv.17002.
［140］	Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52⁃week results from a Phase 3 double⁃blind randomized, controlled trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:938⁃947. doi: 10.1111/jdv.17002.
［141］	Paller AS, Seyger M, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double⁃blind, placebo⁃controlled study in paediatric patients with moderate⁃to⁃severe plaque psoriasis （IXORA⁃PEDS）［J］. Br J Dermatol, 2020,183（2）:231⁃241. doi: 10.1111/bjd.19147.
［142］	Ergun T, Seckin Gencosmanoglu D, Alpsoy E, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study［J］. J Dermatol, 2017,44（6）:630⁃634. doi: 10.1111/1346⁃8138.13713.
［143］	van Geel MJ, Oostveen AM, Hoppenreijs EP, et al. Methotrexate in pediatric plaque⁃type psoriasis: Long⁃term daily clinical practice results from the Child⁃CAPTURE registry［J］. J Dermatolog Treat, 2015,26（5）:406⁃412. doi: 10.3109/09546634.2014.996515.
［144］	Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017［J］. Br J Dermatol, 2017,177（3）:628⁃636. doi: 10.1111/bjd.15665.
［145］	Saxena VN, Dogra J. Long⁃term use of penicillin for the treatment of chronic plaque psoriasis［J］. Eur J Dermatol, 2005,15（5）:359⁃362.
［146］	Saxena VN, Dogra J. Long⁃term oral azithromycin in chronic plaque psoriasis: a controlled trial［J］. Eur J Dermatol, 2010,20（3）:329⁃333. doi: 10.1684/ejd.2010.0930.
［147］	Vincent F, Ross JB, Dalton M, et al. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis［J］. J Am Acad Dermatol, 1992,26（3 Pt 2）:458⁃461. doi: 10.1016/0190⁃9622（92）70072⁃n.
［148］	Dogan B, Karabudak O, Harmanyeri Y. Antistreptococcal treatment of guttate psoriasis: a controlled study［J］. Int J Dermatol, 2008,47（9）:950⁃952. doi: 10.1111/j.1365⁃4632.2008. 03663.x.
［149］	Caca⁃Biljanovska NG, V′Lckova⁃Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study［J］. Croat Med J, 2002,43（6）:707⁃712.
［150］	Rachakonda TD, Dhillon JS, Florek AG, et al. Effect of tonsillectomy on psoriasis: a systematic review［J］. J Am Acad Dermatol, 2015,72（2）:261⁃275. doi: 10.1016/j.jaad.2014.10. 013.
［151］	Thorleifsdottir RH, Eysteinsdóttir JH, Olafsson JH, et al. Throat infections are associated with exacerbation in a substantial proportion of patients with chronic plaque psoriasis［J］. Acta Derm Venereol, 2016,96（6）:788⁃791. doi: 10.2340/00015555⁃2408.
［152］	Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. HLA⁃Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: a prospective case series［J］. J Am Acad Dermatol, 2016,75（5）:889⁃896. doi: 10.1016/j.jaad.2016.06. 061.
［153］	Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Patient⁃reported outcomes and clinical response in patients with moderate⁃to⁃severe plaque psoriasis treated with tonsillectomy: a randomized controlled trial［J］. Acta Derm Venereol, 2017,97（3）:340⁃345. doi: 10.2340/00015555⁃2562.
［154］	Man MQ, Ye L, Hu L, et al. Improvements in epidermal function prevent relapse of psoriasis: a self⁃controlled study［J］. Clin Exp Dermatol, 2019,44（6）:654⁃657. doi: 10.1111/ced.13888.
［155］	Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis［J］. Clin Dermatol, 2008,26（4）:380⁃386. doi: 10.1016/j.clindermatol.2008.01.015.
［156］	Buraczewska I, Berne B, Lindberg M, et al. Changes in skin barrier function following long⁃term treatment with moisturizers, a randomized controlled trial［J］. Br J Dermatol, 2007,156（3）:492⁃498. doi: 10.1111/j.1365⁃2133.2006.07685.x.
［157］	Berne B, Blom I, Spångberg S. Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base. A single⁃blind controlled study［J］. Acta Derm Venereol, 1990,70（6）:474⁃477. doi: 102340/0001555570474477.
［158］	Lukas A, Wolf G, Fölster⁃Holst R. Special features of topical and systemic dermatologic therapy in children［J］. J Dtsch Dermatol Ges, 2006,4（8）:658⁃678; quiz 679⁃680. doi: 10.1111/j.1610⁃0387.2006.05995.x.
［159］	Cork MJ, Danby S. Skin barrier breakdown: a renaissance in emollient therapy［J］. Br J Nurs, 2009,18（14）:872,874,876⁃877. doi: 10.12968/bjon.2009.18.14.43356.
［160］	Liu M, Li X, Chen XY, et al. Topical application of a linoleic acid⁃ceramide containing moisturizer exhibit therapeutic and preventive benefits for psoriasis vulgaris: a randomized controlled trial［J］. Dermatol Ther, 2015,28（6）:373⁃382. doi: 10.1111/dth.12259.
［161］	Green L. Emollient therapy for dry and inflammatory skin conditions［J］. Nurs Stand, 2011,26（1）:39⁃46. doi: 10.7748/ns2011.09.26.1.39.c8692.
［162］	Proksch E, Dähnhardt D, Dähnhardt⁃Pfeiffer S, et al. Epidermal barrier disorders in dermatoses［J］. Hautarzt, 2016,67（11）:907⁃921. doi: 10.1007/s00105⁃016⁃3883⁃2.
［163］	Madan RK, Levitt J. A review of toxicity from topical salicylic acid preparations［J］. J Am Acad Dermatol, 2014,70（4）:788⁃792. doi: 10.1016/j.jaad.2013.12.005.
［164］	Rademaker M, Agnew K, Anagnostou N, et al. Psoriasis and infection. A clinical practice narrative［J］. Australas J Dermatol, 2019,60（2）:91⁃98. doi: 10.1111/ajd.12895.
［165］	Spiera H, Lefkovits AM. Remission of psoriasis with low dietary tryptophan［J］. Lancet, 1967,2（7507）:137⁃139. doi: 10.1016/s0140⁃6736（67）92970⁃4.
［166］	Brown AC, Hairfield M, Richards DG, et al. Medical nutrition therapy as a potential complementary treatment for psoriasis⁃⁃five case reports［J］. Altern Med Rev, 2004,9（3）:297⁃307.
［167］	Festugato M. Pilot study on which foods should be avoided by patients with psoriasis［J］. An Bras Dermatol, 2011,86（6）:1103⁃1108. doi: 10.1590/s0365⁃05962011000600006.
［168］	Kristensen S, Schmidt EB, Schlemmer A, et al. Beneficial effect of n⁃3 polyunsaturated fatty acids on inflammation and analgesic use in psoriatic arthritis: a randomized, double blind, placebo⁃controlled trial［J］. Scand J Rheumatol, 2018,47（1）:27⁃36. doi: 10.1080/03009742.2017.1287304.
［169］	Gupta AK, Ellis CN, Tellner DC, et al. Double⁃blind, placebo⁃controlled study to evaluate the efficacy of fish oil and low⁃dose UVB in the treatment of psoriasis［J］. Br J Dermatol, 1989,120（6）:801⁃807. doi: 10.1111/j.1365⁃2133.1989.tb01378.x.
［170］	Madland TM, Björkkjaer T, Brunborg LA, et al. Subjective improvement in patients with psoriatic arthritis after short⁃term oral treatment with seal oil. A pilot study with double blind comparison to soy oil［J］. J Rheumatol, 2006,33（2）:307⁃310.
［171］	Veale DJ, Torley HI, Richards IM, et al. A double⁃blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis［J］. Br J Rheumatol, 1994,33（10）:954⁃958. doi: 10.1093/rheumatology/33.10.954.
［172］	Søyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very⁃long⁃chain n⁃3 fatty acids in patients with psoriasis［J］. N Engl J Med, 1993,328（25）:1812⁃1816. doi: 10.1056/NEJM199306243282504.
［173］	Strong A , Hamill E . The effect of combined fish oil and evening primrose oil （Efamol Marine） on the remission phase of psoriasis: a 7⁃month double⁃blind randomized placebo⁃controlled trial［J］. J Dermatol Treat, 1993, 4（1）:33⁃36.
［174］	Gupta AK, Ellis CN, Goldfarb MT, et al. The role of fish oil in psoriasis. A randomized, double⁃blind, placebo⁃controlled study to evaluate the effect of fish oil and topical corticosteroid therapy in psoriasis［J］. Int J Dermatol, 1990,29（8）:591⁃595. doi: 10.1111/j.1365⁃4362.1990.tb03477.x.
［175］	Bittiner SB, Tucker WF, Cartwright I, et al. A double⁃blind, randomised, placebo⁃controlled trial of fish oil in psoriasis［J］. Lancet, 1988,1（8582）:378⁃380. doi: 10.1016/s0140⁃6736（88）91181⁃6.
［176］	Bjørneboe A, Smith AK, Bjørneboe GE, et al. Effect of dietary supplementation with n⁃3 fatty acids on clinical manifestations of psoriasis［J］. Br J Dermatol, 1988,118（1）:77⁃83. doi: 10. 1111/j.1365⁃2133.1988.tb01753.x.
［177］	Mayser P, Mrowietz U, Arenberger P, et al. Omega⁃3 fatty acid⁃based lipid infusion in patients with chronic plaque psoriasis: results of a double⁃blind, randomized, placebo⁃controlled, multicenter trial［J］. J Am Acad Dermatol, 1998,38（4）:539⁃547. doi: 10.1016/s0190⁃9622（98）70114⁃8.
［178］	Grimminger F, Mayser P, Papavassilis C, et al. A double⁃blind, randomized, placebo⁃controlled trial of n⁃3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile［J］. Clin Investig, 1993,71（8）:634⁃643. doi: 10.1007/BF00184491.
［179］	Grossman Z, Hadjipanayis A, Stiris T, et al. Vitamin D in European children⁃statement from the European Academy of Paediatrics （EAP）［J］. Eur J Pediatr, 2017,176（6）:829⁃831. doi: 10.1007/s00431⁃017⁃2903⁃2.
［180］	Lee YH, Song GG. Association between circulating 25⁃hydroxyvitamin D levels and psoriasis, and correlation with disease severity: a meta⁃analysis［J］. Clin Exp Dermatol, 2018,43（5）:529⁃535. doi: 10.1111/ced.13381.
［181］	Finamor DC, Sinigaglia⁃Coimbra R, Neves LC, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis［J］. Dermatoendocrinol, 2013,5（1）:222⁃234. doi: 10. 4161/derm.24808.
［182］	Perez A, Raab R, Chen TC, et al. Safety and efficacy of oral calcitriol （1,25⁃dihydroxyvitamin D3） for the treatment of psoriasis［J］. Br J Dermatol, 1996,134（6）:1070⁃1078.
［183］	Morimoto S, Yoshikawa K, Kozuka T, et al. Treatment of psoriasis vulgaris by oral administration of 1 alpha⁃hydroxyvitamin D3⁃⁃open⁃design study［J］. Calcif Tissue Int, 1986,39（3）:209⁃212. doi: 10.1007/BF02555120.
［184］	Smith EL, Pincus SH, Donovan L, et al. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25⁃dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis［J］. J Am Acad Dermatol, 1988,19（3）:516⁃528. doi: 10.1016/s0190⁃9622（88）70207⁃8.
［185］	Takamoto S, Onishi T, Morimoto S, et al. Effect of 1 alpha⁃hydroxycholecalciferol on psoriasis vulgaris: a pilot study［J］. Calcif Tissue Int, 1986,39（6）:360⁃364. doi: 10.1007/BF025 55172.
［186］	el⁃Azhary RA, Peters MS, Pittelkow MR, et al. Efficacy of vitamin D3 derivatives in the treatment of psoriasis vulgaris: a preliminary report［J］. Mayo Clin Proc, 1993,68（9）:835⁃841. doi: 10.1016/s0025⁃6196（12）60690⁃9.
［187］	Holland DB, Wood EJ, Roberts SG, et al. Epidermal keratin levels during oral 1⁃alpha⁃hydroxyvitamin D3 treatment for psoriasis［J］. Skin Pharmacol, 1989,2（2）:68⁃76. doi: 10.1159/000210803.
［188］	Ezquerra GM, Regana MS, Millet PU. Combination of acitretin and oral calcitriol for treatment of plaque⁃type psoriasis［J］. Acta Derm Venereol, 2007,87（5）:449⁃450. doi: 10.2340/000 15555⁃0290.
［189］	Lugo⁃Somolinos A, Sánchez JL, Haddock L. Efficacy of 1, alpha 25⁃dihidroxyvitamin D （Calcitriol） in the treatment of psoriasis vulgaris: an open study［J］. Bol Asoc Med P R, 1990,82（10）:450⁃453.
［190］	Morimoto S, Yoshikawa K, Kozuka T, et al. An open study of vitamin D3 treatment in psoriasis vulgaris［J］. Br J Dermatol, 1986,115（4）:421⁃429. doi: 10.1111/j.1365⁃2133.1986.tb06236.x.
［191］	Jarrett P, Camargo CA Jr, Coomarasamy C, et al. A randomized, double⁃blind, placebo⁃controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis［J］. J Dermatolog Treat, 2018,29（4）:324⁃328. doi: 10.1080/09546634.2017.137 3735.
［192］	Ingram MA, Jones MB, Stonehouse W, et al. Oral vitamin D（3） supplementation for chronic plaque psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Dermatolog Treat, 2018,29（7）:648⁃657. doi: 10.1080/09546634.2018.1444728.
［193］	Siddiqui MA, Al⁃Khawajah MM. Vitamin D3 and psoriasis: a randomized double⁃blind placebo⁃controlled study［J］. J Dermatolog Treat, 1990,1（5）:243⁃245.
［194］	Gaál J, Lakos G, Szodoray P, et al. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow⁃up pilot study［J］. Acta Derm Venereol, 2009,89（2）:140⁃144. doi: 10.2340/00015555⁃0555.
［195］	Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25⁃dihydroxyvitamin D3: a pilot study［J］. Arthritis Rheum, 1990,33（11）:1723⁃1727. doi: 10.1002/art. 1780331117.
［196］	Zhu Z, Zhan J, Shao J, et al. High prevalence of vitamin D deficiency among children aged 1 month to 16 years in Hangzhou, China［J］. BMC Public Health, 2012,12:126. doi: 10.1186/1471⁃2458⁃12⁃126.
［197］	Guo Y, Ke HJ, Liu Y, et al. Prevalence of vitamin D insufficiency among children in southern china: a cross⁃sectional survey［J］. Medicine （Baltimore）, 2018,97（25）:e11030. doi: 10.1097/MD.0000000000011030.
［198］	Strand MA, Perry J, Zhao J, et al. Severe vitamin D⁃deficiency and the health of North China children［J］. Matern Child Health J, 2009,13（1）:144⁃150. doi: 10.1007/s10995⁃007⁃0250⁃z.
［199］	Ruedemann R Jr. Treatment of psoriasis with large doses of vitamin B12, 1,100 micrograms per cubic centimeter; preliminary clinical report［J］. AMA Arch Derm Syphilol, 1954,69（6）:738⁃739. doi: 10.1001/archderm.1954.01540180088013.
［200］	Baker H, Comaish JS. Is vitamin B12 of value in psoriasis?［J］. Br Med J, 1962,2（5321）:1729⁃1730. doi: 10.1136/bmj. 2.5321. 1729.
［201］	Kharaeva Z, Gostova E, De Luca C, et al. Clinical and biochemical effects of coenzyme Q（10）, vitamin E, and selenium supplementation to psoriasis patients［J］. Nutrition, 2009,25（3）:295⁃302. doi: 10.1016/j.nut.2008.08.015.
［202］	Harvima RJ, Jägerroos H, Kajander EO, et al. Screening of effects of selenomethionine⁃enriched yeast supplementation on various immunological and chemical parameters of skin and blood in psoriatic patients［J］. Acta Derm Venereol, 1993,73（2）:88⁃91. doi: 10.2340/00015555738891.
［203］	Serwin AB, Wasowicz W, Chodynicka B. Selenium supplementation, soluble tumor necrosis factor⁃alpha receptor type 1, and C⁃reactive protein during psoriasis therapy with narrowband ultraviolet B［J］. Nutrition, 2006,22（9）:860⁃864. doi: 10.1016/j.nut.2006.05.011.
［204］	Serwin AB, Mysliwiec H, Hukalowicz K, et al. Soluble tumor necrosis factor⁃alpha receptor type 1 during selenium supplementation in psoriasis patients［J］. Nutrition, 2003,19（10）:847⁃850. doi: 10.1016/s0899⁃9007（03）00165⁃5.
［205］	Fairris GM, Lloyd B, Hinks L, et al. The effect of supplementation with selenium and vitamin E in psoriasis［J］. Ann Clin Biochem, 1989,26（Pt 1）:83⁃88. doi: 10.1177/000456 328902600113.
［206］	Pludowski P, Holick MF, Grant WB, et al. Vitamin D supplementation guidelines［J］. J Steroid Biochem Mol Biol, 2018,175:125⁃135. doi: 10.1016/j.jsbmb.2017.01.021.
［207］	Braegger C, Campoy C, Colomb V, et al. Vitamin D in the healthy European paediatric population［J］. J Pediatr Gastroenterol Nutr, 2013,56（6）:692⁃701. doi: 10.1097/MPG. 0b013e31828f3c05.
［208］	Chen W, Zhou X, Zhu W. Trace elements homeostatic imbalance in psoriasis: a meta⁃analysis［J］. Biol Trace Elem Res, 2019,191（2）:313⁃322. doi: 10.1007/s12011⁃018⁃1626⁃1.
［209］	Witman PM. Topical therapies for localized psoriasis［J］. Mayo Clin Proc, 2001,76（9）:943⁃949. doi: 10.4065/76.9.943.
［210］	Jacobi A, Mayer A, Augustin M. Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review［J］. Dermatol Ther （Heidelb）, 2015,5（1）:1⁃18. doi: 10.1007/s13555⁃015⁃0068⁃3.
［211］	Childhood psoriasis: often favorable outcome［J］. Prescrire Int, 2009,18（104）:275.
［212］	Dawn A, Yosipovitch G. Treating itch in psoriasis［J］. Dermatol Nurs, 2006,18（3）:227⁃233.
［213］	Pauporte M, Maibach H, Lowe N, et al. Fluocinolone acetonide topical oil for scalp psoriasis［J］. J Dermatolog Treat, 2004,15（6）:360⁃364. doi: 10.1080/09546630410023566.
［214］	van Duijnhoven MW, Hagenberg R, Pasch MC, et al. Novel quantitative immunofluorescent technique reveals improvements in epidermal cell populations after mild treatment of psoriasis［J］. Acta Derm Venereol, 2005,85（4）:311⁃317. doi: 10.1080/00015550510027757.
［215］	Rim JH, Jo SJ, Park JY, et al. Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients［J］. Clin Exp Dermatol, 2005,30（4）:409⁃413. doi: 10.1111/j.1365⁃2230.2005.01773.x.
［216］	Kanzler MH, Gorsulowsky DC. Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis［J］. Br J Dermatol, 1993,129（3）:310⁃314. doi: 10. 1111/j.1365⁃2133.1993.tb11852.x.
［217］	Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis［J］. Indian Dermatol Online J, 2016,7（6）:481⁃488. doi: 10.4103/2229⁃5178.193908.
［218］	Greaves MW, Weinstein GD. Treatment of psoriasis［J］. N Engl J Med, 1995,332（9）:581⁃588. doi: 10.1056/NEJM199503023 320907.
［219］	Van Onselen J. An overview of psoriasis and the role of emollient therapy［J］. Br J Community Nurs, 2013,18（4）:174⁃179. doi: 10.12968/bjcn.2013.18.4.174.
［220］	Jerajani HR, Thomas J, Gupta A, et al. A real⁃world, non⁃interventional Indian study evaluating intensive plant⁃based butter moisturizing cream in psoriasis［J］. Dermatol Ther （Heidelb）, 2019,9（3）:537⁃546. doi: 10.1007/s13555⁃019⁃0307⁃0.
［221］	Watsky KL, Freije L, Leneveu MC, et al. Water⁃in⁃oil emollients as steroid⁃sparing adjunctive therapy in the treatment of psoriasis［J］. Cutis, 1992,50（5）:383⁃386.
［222］	Seité S, Khemis A, Rougier A, et al. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis［J］. Exp Dermatol, 2009,18（12）:1076⁃1078. doi: 10.1111/j.1600⁃0625. 2009.00903.x.
［223］	Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid［J］. Cutis, 2000,66（6 Suppl）:4⁃11.
［224］	Cassano N, Mantegazza R, Battaglini S, et al. Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot randomized open⁃label study［J］. G Ital Dermatol Venereol, 2010,145（6）:789⁃792.
［225］	Sticherling M, Augustin M, Boehncke WH, et al. Therapy of psoriasis in childhood and adolescence ⁃ a German expert consensus［J］. J Dtsch Dermatol Ges, 2011,9（10）:815⁃823. doi: 10.1111/j.1610⁃0387.2011.07668.x.
［226］	Boyvat A, Erdi H, Birol A, et al. Interaction of commonly used emollients with photochemotherapy［J］. Photodermatol Photoimmunol Photomed, 2000,16（4）:156⁃160. doi: 10.1034/j.1600⁃0781.2000.160402.x.
［227］	Abdallah MA, El⁃Khateeb EA, Abdel⁃Rahman SH. The influence of psoriatic plaques pretreatment with crude coal tar vs. petrolatum on the efficacy of narrow⁃band ultraviolet B: a half⁃vs.⁃half intra⁃individual double⁃blinded comparative study［J］. Photodermatol Photoimmunol Photomed, 2011,27（5）:226⁃230. doi: 10.1111/j.1600⁃0781.2011.00602.x.
［228］	Penven K, Leroy D, Verneuil L, et al. Evaluation of vaseline oil applied prior to UVB TL01 phototherapy in the treatment of psoriasis［J］. Photodermatol Photoimmunol Photomed, 2005,21（3）:138⁃141. doi: 10.1111/j.1600⁃0781.2005.00157.x.
［229］	Lebwohl M, Martinez J, Weber P, et al. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy［J］. J Am Acad Dermatol, 1995,32（3）:469⁃471. doi: 10.1016/0190⁃9622（95）90071⁃3.
［230］	Kristensen B, Kristensen O. Topical salicylic acid interferes with UVB therapy for psoriasis［J］. Acta Derm Venereol, 1991,71（1）:37⁃40.
［231］	Dressler C, Lambert J, Grine L, et al. Therapeutic patient education and self⁃management support for patients with psoriasis ⁃ a systematic review［J］. J Dtsch Dermatol Ges, 2019,17（7）:685⁃695. doi: 10.1111/ddg.13840.

[1]	刘燕邱林傅跃先田晓菲袁心刚肖军李天武毛小波梅爱莲郭永强周荣. 儿童甲母痣35例外科治疗效果分析[J]. 中华皮肤科杂志, 2022, 0(4): 20201040-e20201040.
[2]	张宁, 李舒, 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 0(4): 20200767-e20200767.
[3]	王玥严煜林. 寻常型银屑病患者171例阿维A治疗相关不良反应及停药原因分析[J]. 中华皮肤科杂志, 2022, 55(3): 242-245.
[4]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.
[5]	王召阳陈安薇向欣罗晓燕徐子刚王华马琳. 基于两家儿童医院信息系统的儿童银屑病现状调查[J]. 中华皮肤科杂志, 2022, 55(3): 246-250.
[6]	李浩, 王俐韩宪伟孙彤苏芳孙晓冬韩莹杨国玲刘晓明王凯波 . 糖尿病患者服用二肽基肽酶Ⅳ抑制剂后发生大疱性类天疱疮32例临床特征分析[J]. 中华皮肤科杂志, 2022, 55(3): 213-218.
[7]	韩晓锋孙娟邱磊尉莉马琳. 儿童穿通型毛母质瘤29例临床病理特点分析[J]. 中华皮肤科杂志, 2022, 55(3): 196-199.
[8]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[9]	王娟娟陈容季江苏文星魏钰倩赵莹尹兴平苏玉华施辛. 以精神行为异常为首发症状的67例神经梅毒患者回顾性分析[J]. 中华皮肤科杂志, 2022, 55(3): 231-234.
[10]	吕玲吕小岩. 皮肌炎伴发恶性肿瘤的研究进展[J]. 中华皮肤科杂志, 2022, 55(3): 276-279.
[11]	李锁向睿宇李志量荆可王媛张寒梅冯素英. 盐裂皮肤间接免疫荧光技术在大疱性类天疱疮诊断中的价值评估[J]. 中华皮肤科杂志, 2022, 55(3): 235-237.
[12]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[13]	包诗杰, 程杨, 晏莹, 范昉, 高婷婷, 冯小兰, 郑亮, 雷卫, 黄琴斯, 张伟明, 周小勇. 人免疫球蛋白和重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的对比研究[J]. 中华皮肤科杂志, 2022, 55(2): 153-156.
[14]	欧敏, 颜韵灵, 郑宝庆, 王晓华. 银屑病与肥胖相关性的研究进展[J]. 中华皮肤科杂志, 2022, 55(2): 181-184.
[15]	张婷婷朱凤仪杨梅张平夏萍周小勇. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210644-e20210644.

中国儿童银屑病诊疗专家共识（2021）

Consensus on the diagnosis and treatment of childhood psoriasis in China （2021）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 231

相关文章 15

Metrics

本文评价

推荐阅读 10